BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Trametinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Trametinib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04185883-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Trametinib: Phase 1 readout est. (NCT04185883)
DESCRIPTION:Trametinib\, phase 1.\nStudy: Sotorasib Activity in Subjects Wi
 th Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)\nEstima
 ted primary completion: 17 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04185883
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06653517-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trametinib: Phase 2 readout est. (NCT06653517)
DESCRIPTION:Trametinib\, phase 2.\nStudy: Clinical Study of Neoadjuvant Tar
 geted Therapy for Ameloblastoma\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0665351
 7
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739395-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trametinib: Phase 2 readout est. (NCT06739395)
DESCRIPTION:Trametinib\, phase 2.\nStudy: Precision Medicine Trial Based on
  Molecular Matching Therapy for Patients With Standard Treatment Exhaustio
 n\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06739395
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06195228-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trametinib: Phase 4 readout est. (NCT06195228)
DESCRIPTION:Trametinib\, phase 4.\nStudy: A Retrospective and Prospective R
 eal-world Study of Molecular Typing in the Treatment of Advanced Thyroid C
 ancer\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06195228
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06079333-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Trametinib: Phase 2 readout est. (NCT06079333)
DESCRIPTION:Trametinib\, phase 2.\nStudy: NEO- and Adjuvant Targeted Therap
 y in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)\nEsti
 mated primary completion: 1 January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06079333
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03087071-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Trametinib: Phase 2 readout est. (NCT03087071)
DESCRIPTION:Trametinib\, phase 2.\nStudy: Panitumumab With or Without Trame
 tinib in Treating Patients With Stage IV Colorectal Cancer\nEstimated prim
 ary completion: 31 January 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/trametinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT03087071
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04417621-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Trametinib: Phase 2 readout est. (NCT04417621)
DESCRIPTION:Trametinib\, phase 2\, Melanoma.\nStudy: Study of Efficacy and 
 Safety of LXH254 Combinations in Patients With Previously Treated Unresect
 able or Metastatic Melanoma\nEstimated primary completion: 2 February 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04417621
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03363217-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Trametinib: Phase 2 readout est. (NCT03363217)
DESCRIPTION:Trametinib\, phase 2\, Glioma.\nStudy: Trametinib for Pediatric
  Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/
 ERK Pathway.\nEstimated primary completion: 1 March 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03363217
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02196181-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Trametinib: Phase 2 readout est. (NCT02196181)
DESCRIPTION:Trametinib\, phase 2\, Melanoma.\nStudy: Testing Two Different 
 Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has
  Spread\nEstimated primary completion: 15 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT02196181
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04111458-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Trametinib: Phase 1 readout est. (NCT04111458)
DESCRIPTION:Trametinib\, phase 1.\nStudy: A Study to Test Different Doses o
 f BI 1701963 Alone and Combined With Trametinib in Patients With Different
  Types of Advanced Cancer (Solid Tumours With KRAS Mutation)\nEstimated pr
 imary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/trametinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04111458
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02231775-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Trametinib: Phase 2 readout est. (NCT02231775)
DESCRIPTION:Trametinib\, phase 2\, Melanoma.\nStudy: Dabrafenib and Trameti
 nib Before and After Surgery in Treating Patients With Stage IIIB-C Melano
 ma With BRAF V600 Mutation\nEstimated primary completion: 1 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT02231775
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04238624-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Trametinib: Phase 2 readout est. (NCT04238624)
DESCRIPTION:Trametinib\, phase 2.\nStudy: Study of Cemiplimab Combined With
  Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer\nEstim
 ated primary completion: 20 June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04238624
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04943224-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trametinib: Phase 2 readout est. (NCT04943224)
DESCRIPTION:Trametinib\, phase 2.\nStudy: Optimization of the Time and Dosa
 ge of Trametinib in BRAF Negative Juvenile Patients\nEstimated primary com
 pletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/trametinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04943224
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07072403-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT07072403)
DESCRIPTION:Trametinib\, phase 1/2.\nStudy: Trametinib Treatment for Compli
 cated Vascular Anomalies\nEstimated primary completion: 1 July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07072403
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03333343-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270712
DTEND;VALUE=DATE:20270713
SUMMARY:Trametinib: Phase 1 readout est. (NCT03333343)
DESCRIPTION:Trametinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NS
 CLC\nEstimated primary completion: 12 July 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03333343
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06804824-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Trametinib: Phase 1 readout est. (NCT06804824)
DESCRIPTION:Trametinib\, phase 1.\nStudy: A First-in-Human (FIH) Study to E
 valuate the Safety and Tolerability of VVD-159642 in Participants With Adv
 anced Solid Tumors\nEstimated primary completion: 1 August 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06804824
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03085056-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Trametinib: Phase 1 readout est. (NCT03085056)
DESCRIPTION:Trametinib\, phase 1.\nStudy: Trametinib in Combination With Pa
 clitaxel in the Treatment of Anaplastic Thyroid Cancer\nEstimated primary 
 completion: September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/trametinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03085056
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Trametinib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Trametinib\, phase 2.\nStudy: The Drug Rediscovery Protocol (DR
 UP Trial)\nEstimated primary completion: September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04544111-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270902
DTEND;VALUE=DATE:20270903
SUMMARY:Trametinib: Phase 2 readout est. (NCT04544111)
DESCRIPTION:Trametinib\, phase 2.\nStudy: PDR001 Combination Therapy for Ra
 dioiodine-Refractory Thyroid Cancer\nEstimated primary completion: 2 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trametinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT045
 44111
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05525273-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270910
DTEND;VALUE=DATE:20270911
SUMMARY:Trametinib: Phase 2 readout est. (NCT05525273)
DESCRIPTION:Trametinib\, phase 2.\nStudy: Treatment of BRAF ( B-Rapidly Acc
 elerated Fibrosarcoma) Mutated Papillary Craniopharyngioma\nEstimated prim
 ary completion: 10 September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/trametinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05525273
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03919071-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Trametinib: Phase 2 readout est. (NCT03919071)
DESCRIPTION:Trametinib\, phase 2\, Glioma.\nStudy: Dabrafenib Combined With
  Trametinib After Radiation Therapy in Treating Patients With Newly-Diagno
 sed High-Grade Glioma\nEstimated primary completion: 30 September 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03919071
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890701-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT07890701)
DESCRIPTION:Trametinib\, phase 1/2.\nStudy: A Single-Arm\,Multicenter Phase
 \, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the 
 Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Childre
 n and Adolescents\nEstimated primary completion: 1 October 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07890701
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Trametinib: Phase 2 readout est. (NCT06563999)
DESCRIPTION:Trametinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harb
 oring Rare Mutations.\nEstimated primary completion: 1 November 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06563999
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06967155-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20271110
DTEND;VALUE=DATE:20271111
SUMMARY:Trametinib: Phase 2 readout est. (NCT06967155)
DESCRIPTION:Trametinib\, phase 2.\nStudy: A Study of Irinotecan With Dabraf
 enib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People
  With Metastatic Colorectal Cancer\nEstimated primary completion: 10 Novem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trametinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0696
 7155
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05874414-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT05874414)
DESCRIPTION:Trametinib\, phase 1/2.\nStudy: Combination of GNS561 and Trame
 tinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma\nEstimated
  primary completion: December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trametinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05874414
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02910700-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20271208
DTEND;VALUE=DATE:20271209
SUMMARY:Trametinib: Phase 2 readout est. (NCT02910700)
DESCRIPTION:Trametinib\, phase 2\, Melanoma.\nStudy: Nivolumab With Trameti
 nib and Dabrafenib\, or Encorafenib and Binimetinib in Treating Patients W
 ith BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma\nEstimat
 ed primary completion: 8 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02910700
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05275374-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT05275374)
DESCRIPTION:Trametinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: XP
 -102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Pat
 ients With a BRAF V600 Mutation\nEstimated primary completion: 30 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0527537
 4
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04485559-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trametinib: Phase 1 readout est. (NCT04485559)
DESCRIPTION:Trametinib\, phase 1\, Glioma.\nStudy: Trametinib and Everolimu
 s for Treatment of Pediatric and Young Adult Patients With Recurrent Gliom
 as (PNOC021)\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04485559
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03225664-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT03225664)
DESCRIPTION:Trametinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Tr
 ametinib and Pembrolizumab in Treating Patients With Recurrent Non-small C
 ell Lung Cancer That Is Metastatic\, Unresectable\, or Locally Advanced\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03225664
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01989585-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT01989585)
DESCRIPTION:Trametinib\, phase 1/2\, Melanoma.\nStudy: Testing the Addition
  of Navitoclax to the Combination of Dabrafenib and Trametinib in People W
 ho Have BRAF Mutant Melanoma\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT01989585
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02693535-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trametinib: Phase 2 readout est. (NCT02693535)
DESCRIPTION:Trametinib\, phase 2.\nStudy: TAPUR: Testing the Use of Food an
 d Drug Administration (FDA) Approved Drugs That Target a Specific Abnormal
 ity in a Tumor Gene in People With Advanced Stage Cancer\nEstimated primar
 y completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/trametinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT02693535
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trametinib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Trametinib\, phase 2\, Melanoma.\nStudy: Targeted Therapy Direc
 ted by Genetic Testing in Treating Patients With Advanced Refractory Solid
  Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010393-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trametinib: Phase 4 readout est. (NCT07010393)
DESCRIPTION:Trametinib\, phase 4.\nStudy: Genotype-Driven Neoadjuvant Thera
 py for Locally Advanced Thyroid Cancer: A Real-World Cohort Study\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07010393
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477457-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trametinib: Phase 2 readout est. (NCT07477457)
DESCRIPTION:Trametinib\, phase 2.\nStudy: A Study of Gefitinib\, Trametinib
 \, Disulfiram\, and Sunitinib in Addition to Standard Chemotherapy in Peop
 le With Osteosarcoma\nEstimated primary completion: March 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07477457
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962254-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trametinib: Phase 1 readout est. (NCT06962254)
DESCRIPTION:Trametinib\, phase 1.\nStudy: Imatinib and Trametinib for KRAS-
 mutated Solid Tumor\nEstimated primary completion: 31 March 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06962254
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131059-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20280510
DTEND;VALUE=DATE:20280511
SUMMARY:Trametinib: Phase na readout est. (NCT07131059)
DESCRIPTION:Trametinib\, phase na.\nStudy: MRD-positive AML Clinical Study\
 nEstimated primary completion: 10 May 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07131059
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786924-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT05786924)
DESCRIPTION:Trametinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignanc
 ies\nEstimated primary completion: June 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05786924
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07022834-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Trametinib: Phase 2 readout est. (NCT07022834)
DESCRIPTION:Trametinib\, phase 2.\nStudy: Real-world Study of Darafenib or 
 Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans C
 ell Histiocytosis in Children\nEstimated primary completion: 1 June 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07022834
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04903119-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Trametinib: Phase 1 readout est. (NCT04903119)
DESCRIPTION:Trametinib\, phase 1\, Melanoma.\nStudy: Nilotinib Plus Dabrafe
 nib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma\nEstimate
 d primary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/trametinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04903119
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04675710-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Trametinib: Phase 2 readout est. (NCT04675710)
DESCRIPTION:Trametinib\, phase 2.\nStudy: Pembrolizumab\, Dabrafenib\, and 
 Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thy
 roid Cancer\nEstimated primary completion: 30 October 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04675710
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819605-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Trametinib: Phase 2/3 readout est. (NCT06819605)
DESCRIPTION:Trametinib\, phase 2/3.\nStudy: Neoadjuvant Therapy With Conser
 vative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Am
 eloblastoma\nEstimated primary completion: 30 October 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06819605
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712875-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT06712875)
DESCRIPTION:Trametinib\, phase 1/2\, Glioma.\nStudy: MAPK Inhibition Combin
 ed With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/trametinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06712875
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05849662-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT05849662)
DESCRIPTION:Trametinib\, phase 1/2.\nStudy: A Phase I/II Study of Trametini
 b and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocyti
 c Leukemia\nEstimated primary completion: December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05849662
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04803318-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Trametinib: Phase 2 readout est. (NCT04803318)
DESCRIPTION:Trametinib\, phase 2.\nStudy: Trametinib Combined With Everolim
 us and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors\nEstimate
 d primary completion: 1 January 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/trametinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04803318
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05658640-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT05658640)
DESCRIPTION:Trametinib\, phase 1/2.\nStudy: HEM iSMART-D: Trametinib + Dexa
 methasone + Chemotherapy in Children With Relapsed or Refractory Hematolog
 ical Malignancies\nEstimated primary completion: 1 April 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05658640
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07886905-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20290408
DTEND;VALUE=DATE:20290409
SUMMARY:Trametinib: Phase 2 readout est. (NCT07886905)
DESCRIPTION:Trametinib\, phase 2.\nStudy: Pulsed Stereotactic Ablative Radi
 otherapy (PULSAR) With Systematic Therapy for Thyroid Cancer\nEstimated pr
 imary completion: 8 April 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/trametinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07886905
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07468071-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20290611
DTEND;VALUE=DATE:20290612
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT07468071)
DESCRIPTION:Trametinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ro
 llover Study for Participants Who Have Been Treated With and Are Continuin
 g to Benefit From Opnurasib as a Single Agent or in Combination With Other
  Study Treatments\nEstimated primary completion: 11 June 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07468071
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899155-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20290825
DTEND;VALUE=DATE:20290826
SUMMARY:Trametinib: Phase 2 readout est. (NCT03899155)
DESCRIPTION:Trametinib\, phase 2.\nStudy: Pan Tumor Rollover Study\nEstimat
 ed primary completion: 25 August 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03899155
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05722886-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Trametinib: Phase 2/3 readout est. (NCT05722886)
DESCRIPTION:Trametinib\, phase 2/3.\nStudy: DETERMINE (Determining Extended
  Therapeutic Indications for Existing Drugs in Rare Molecularly Defined In
 dications Using a National Evaluation Platform Trial) - Master Screening P
 rotocol\nEstimated primary completion: October 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05722886
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07440290-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Trametinib: Phase 2/3 readout est. (NCT07440290)
DESCRIPTION:Trametinib\, phase 2/3\, Glioma.\nStudy: DETERMINE Trial Treatm
 ent Arm 07: Dabrafenib in Combination With Trametinib in Adult\, Paediatri
 c and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancer
 s.\nEstimated primary completion: October 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07440290
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549646-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20291027
DTEND;VALUE=DATE:20291028
SUMMARY:Trametinib: Phase 2 readout est. (NCT07549646)
DESCRIPTION:Trametinib\, phase 2.\nStudy: 24VA021\; VATCH Trametinib for Ra
 s/MAPK Pathway VAs\nEstimated primary completion: 27 October 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07549646
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05180825-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20311101
DTEND;VALUE=DATE:20311102
SUMMARY:Trametinib: Phase 2 readout est. (NCT05180825)
DESCRIPTION:Trametinib\, phase 2\, Glioma.\nStudy: Pediatric Low Grade Glio
 ma - MEKinhibitor TRIal vs Chemotherapy\nEstimated primary completion: 1 N
 ovember 2031. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trameti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05180825
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05159245-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20311125
DTEND;VALUE=DATE:20311126
SUMMARY:Trametinib: Phase 2 readout est. (NCT05159245)
DESCRIPTION:Trametinib\, phase 2.\nStudy: The Finnish National Study to Fac
 ilitate Patient Access to Targeted Anti-cancer Drugs\nEstimated primary co
 mpletion: 25 November 2031. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/trametinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05159245
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07110246-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Trametinib: Phase 2 readout est. (NCT07110246)
DESCRIPTION:Trametinib\, phase 2\, Glioma.\nStudy: Dabrafenib and Trametini
 b for BRAF V600 Mutant Low-Grade Gliomas\nEstimated primary completion: 31
  March 2032. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trametin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7110246
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817186-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Trametinib: Phase 3 readout est. (NCT07817186)
DESCRIPTION:Trametinib\, phase 3.\nStudy: Clinical Trial of a MEK Inhibitor
  for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Ba
 by MERIT\nEstimated primary completion: 30 June 2032. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07817186
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03340506-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20321228
DTEND;VALUE=DATE:20321229
SUMMARY:Trametinib: Phase 4 readout est. (NCT03340506)
DESCRIPTION:Trametinib\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: Dabr
 afenib and/or Trametinib Rollover Study\nEstimated primary completion: 28 
 December 2032. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tramet
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03340506
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06119789-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20331130
DTEND;VALUE=DATE:20331201
SUMMARY:Trametinib: Phase 2 readout est. (NCT06119789)
DESCRIPTION:Trametinib\, phase 2.\nStudy: Precision Cancer Therapy in Rare 
 Cancers\nEstimated primary completion: 30 November 2033. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06119789
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06582745-1979@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20390630
DTEND;VALUE=DATE:20390701
SUMMARY:Trametinib: Phase 2 readout est. (NCT06582745)
DESCRIPTION:Trametinib\, phase 2.\nStudy: Targeted Approach to Langerhans C
 ell Histiocytosis (LCH) Using MEK Inhibitor\, Trametinib\nEstimated primar
 y completion: June 2039. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/trametinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06582745
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
